| Online-Ressource |
Verfasst von: | Stacchiotti, Silvia [VerfasserIn]  |
| Van der Graaf, Winette T. A. [VerfasserIn]  |
| Sanfilippo, Roberta G. [VerfasserIn]  |
| Marreaud, Sandrine I. [VerfasserIn]  |
| Van Houdt, Winan J. [VerfasserIn]  |
| Judson, Ian R. [VerfasserIn]  |
| Gronchi, Alessandro [VerfasserIn]  |
| Gelderblom, Hans [VerfasserIn]  |
| Litiere, Saskia [VerfasserIn]  |
| Kasper, Bernd [VerfasserIn]  |
Titel: | First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma |
Titelzusatz: | an EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis |
Verf.angabe: | Silvia Stacchiotti, Winette T.A. Van der Graaf, Roberta G. Sanfilippo, Sandrine I. Marreaud, Winan J. Van Houdt, Ian R. Judson, Alessandro Gronchi, Hans Gelderblom, Saskia Litiere, and Bernd Kasper |
E-Jahr: | 2022 |
Jahr: | 13 May 2022 |
Umfang: | 7 S. |
Fussnoten: | Gesehen am 06.11.2023 |
Titel Quelle: | Enthalten in: Cancer |
Ort Quelle: | New York, NY : Wiley-Liss, 1948 |
Jahr Quelle: | 2022 |
Band/Heft Quelle: | 128(2022), 15 vom: Aug., Seite 2932-2938 |
ISSN Quelle: | 1097-0142 |
Abstract: | BACKGROUND No prospective trial with anthracycline-based chemotherapy has individually assessed response in a well-differentiated (WD)/dedifferentiated (DD) liposarcoma patient cohort. We conducted a retrospective analysis of first-line chemotherapy in liposarcoma of intra-abdominal origin (IA-LPS) in patients who had entered the European Organisation for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG) trials. METHODS We searched for all adult patients treated with first-line chemotherapy for advanced IA-LPS in the EORTC STBSG phase 2 and 3 trials from 1978. Treatment was aggregated into 5 groups: anthracycline alone, ifosfamide alone, doxorubicin plus ifosfamide (D+IFO), doxorubicin/cyclophosphamide/vincristine/dacarbazine, and “other” (brostallicin, trabectedin). Response was assessed prospectively by Response Evaluation Criteria in Solid Tumors or World Health Organization criteria. Progression-free survival (PFS) and overall survival (OS) were computed by Kaplan-Meier method. RESULTS A total of 109 patients with IA-LPS from 13 trials were identified (104 evaluable for response). Overall, there were 10/109 (9.2%) responders: 3/48 (6.3%) in the anthracycline alone group, 2/15 (13%) in the ifosfamide alone group, and 4/18 (22%) in the D+IFO group. At the 10-month median follow-up (interquartile range, 6-24), the median OS was 19 months (95% CI, 15-21) and median PFS 4 months (95% CI, 3-6). D+IFO achieved a not statistically significant longer median PFS (12 months) and median OS (31 months) than observed with other regimens. Univariate/multivariate analysis did not identify prognostic factors. CONCLUSIONS Cytotoxic chemotherapy, in particular anthracycline alone, had marginal activity in advanced IA-LPS. Ifosfamide-containing regimens showed higher activity, although it was not statistically significant and in a small number of cases, with the combination of doxorubicin and ifosfamide appearing to be the more active regimen available in fit patients. This series provides a benchmark for future trials on new drugs in WD/DD liposarcoma.; |
DOI: | doi:10.1002/cncr.34264 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.1002/cncr.34264 |
| kostenfrei: Volltext: http://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.34264 |
| DOI: https://doi.org/10.1002/cncr.34264 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | anthracycline |
| chemotherapy |
| doxorubicin |
| epirubicin |
| ifosfamide |
| liposarcoma |
| sarcoma |
K10plus-PPN: | 1869367596 |
Verknüpfungen: | → Zeitschrift |
First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma / Stacchiotti, Silvia [VerfasserIn]; 13 May 2022 (Online-Ressource)